Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis

References

• Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001; 10: 269–280
   PubMed Web of Science ®Google Scholar
• Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise?. Int J Clin Pract 2001; 55: 633–638
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000; 38(Suppl 1)335–347
   PubMedGoogle Scholar
• Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46: 485–487
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44: 619–621
   PubMed Web of Science ®Google Scholar
• Maesaki S, Hossain MA, Miyazaki Y, et al. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44: 1728–1730
   PubMed Web of Science ®Google Scholar
• Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44: 2259–2262
   PubMed Web of Science ®Google Scholar
• Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614–618
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57–62
   PubMed Web of Science ®Google Scholar
• Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999; 52: 674–676
   PubMed Web of Science ®Google Scholar
• Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53: 1175–1181
   PubMed Web of Science ®Google Scholar
• Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45: 3310–3321
   PubMed Web of Science ®Google Scholar
• Muller FM, Kurzai O, Hacker J, Frosch M, Muhlschlegel F. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 2001; 48: 713–715
   PubMed Web of Science ®Google Scholar
• Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120–135
   PubMedGoogle Scholar
• Denning DW. Treatment of invasive aspergillosis. J Infect 1994; 28(Suppl 1)25–33
   PubMedGoogle Scholar
• Denning, DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–803.
   PubMed Web of Science ®Google Scholar
• Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201
   PubMedGoogle Scholar
• Capilla Luque J, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47: 1452–1455
   PubMed Web of Science ®Google Scholar
• Clemons, KV, Martinez, M, Stevens, DA. Efficacy of itraconazole alone and in combination with amphotericin B against pulmonary aspergillosis. In:. 4th Congress of the European Confederation of Medical Mycology; 1998; GlasgowScotland, 1998: abst. 153.
   Google Scholar
• Hector RF, Yee E, Collins MS. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990; 58: 1476–1478
   PubMed Web of Science ®Google Scholar
• Denning DW, Clemons KV, Stevens DA. Quantitative preservation of viability of Aspergillus fumigatus. J Med Vet Mycol 1992; 30: 485–488
   PubMedGoogle Scholar
• Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35: 1329–1333
   PubMed Web of Science ®Google Scholar
• Hanson LH, Clemons KV, Denning DW, Stevens DA. Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 1995; 33: 311–317
   PubMedGoogle Scholar
• Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992; 36: 477–480
   PubMed Web of Science ®Google Scholar
• Hostetler JS, Hanson LH, Stevens DA. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother 1993; 32: 459–463
   PubMedGoogle Scholar
• Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrobial Agents and Chemotherapy 2000; 44: 378–381
   PubMed Web of Science ®Google Scholar